GlassScriptPhysician profile
Amir Salim
NPI 1619901006
$30,388.88
in general payments reported to CMS, 2019-2025
68 companies · $4,785 in 2025
The $4,785 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,791 · 2020: $3,457 · 2021: $5,877 · 2022: $3,800 · 2023: $3,785 · 2024: $4,895 · 2025: $4,785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $209 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,239.42 |
| Education | $209.26 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,615.85 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $2,644.99 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amarin Pharma, INC. | $2,421.87 | 2019-2023 | |
| Abbvie INC. | $2,280.40 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $1,668.04 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $1,443.65 | 2021-2025 | |
| Amgen INC. | $1,321.49 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Glaxosmithkline, LLC. | $1,284.97 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Biohaven Pharmaceuticals, INC. | $1,270.52 | 2021 | |
| Axsome Therapeutics, INC. | $784.95 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $736.44 | 2022-2025 | Caplyta |
| Pfizer INC. | $666.20 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $619.94 | 2019-2024 | |
| Merz North America, INC. | $613.98 | 2020-2023 | Xeomin |
| Astellas Pharma US INC | $565.02 | 2020-2025 | Veozah |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Salim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.